STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 September 2004 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
On  10  September  1998  the  marketing  authorisation  holder  submitted  a  request  pursuant  to 
Article 10(3) of Council Directive 92/27/EEC in order to change the package leaflet with regard 
to the address of the local representative for Optison in the Netherlands. A Notification (N01) 
was  duly  prepared, and the revised Decision was issued by  the  Commission on 19 November 
1998. 
On 5 October 1998 the Marketing Authorisation Holder submitted to the EMEA an application 
for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995,  as  amended.  The  scope  of  this  variation  was  to  include  Mallinckrodt  Medical  Imaging 
Ireland  as  an  additional  site  for  the  labelling  and  packaging  of  Optison  bulk  material.  This 
variation  was  approved  by  the  EMEA  on  5  November  1998  and  did  not  require  any 
amendments to the Commission Decision 
On  5  October  1998  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  two 
applications for Type I variations in accordance with Commission Regulation (EC) No. 542/95 
of  10  March  1995,  as  amended,  arising  from  the  marketing  authorisation  holder’s  Follow  Up 
Measure  commitments.  I/03  was  a  request  to  add  a  limit  test  for  albumin  aggregates  into  the 
product specification rejected on grounds of insufficient supporting data). I/04 related to a test 
with  limits  for  content  of  octafluoropropane  in  the  product.  Following  an  extension  of  the 
procedure  for  additional  data,  this  variation  was  approved  on  18  December  1998  and  did  not 
require any amendments to the Commission Decision 
An  application  to  amend  the  contact  addresses  in  the  package  leaflet  was  approved  by 
Notification under Article 10(3) of Council Directive 92/27/EEC, on 18 May 1999. A revised 
Commission Decision was issued 29 June 1999. 
On 31 March 1999 the Marketing Authorisation Holder submitted to the EMEA an application 
for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995,  as  amended.  The  scope  of  this  variation  was  a  change  in  in-process  controls  applied 
during  the  manufacture  of  the  product.  This  variation  was  approved  by  the  EMEA  on  4  May 
1999 and did not require any amendments to the Commission Decision. 
On 21 April 1999 the Marketing Authorisation Holder submitted to the EMEA an application 
for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995, as amended. The scope of this variation was to register FluoroMed, L.P. as an additional 
alternative  supplier  of  an  intermediate  compound  used  in  the  manufacture  of  the  active 
substance. The CPMP at the May 1999 plenary meeting adopted a request for the new site to be 
inspected. The procedure was therefore extended. This variation was approved by the EMEA on 
19 August 1999 and did not require any amendments to the Commission Decision. 
An  application  to  amend  the  contact  addresses  in  the  package  leaflet  was  approved  by 
Notification under Article 10(3) of Council Directive 92/27/EEC, on 27 January 2000.  
On 7 April 2000 the Marketing Authorisation Holder submitted to the EMEA two applications 
for  Type I variations in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995, as amended. The scope of these variations was a change in the specifications of excipients 
in the medicinal product and a minor change in the manufacture of the medicinal product. This 
variations were approved by the EMEA on 8 May 2000 and did not require any amendments to 
the Commission Decision. 
On 18 April 2000 the Marketing Authorisation Holder submitted to the EMEA an application 
for  a  Type  II  variation  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10 
March 1995, as amended. The scope of this variation was to update the SPC and the Package 
Leaflet  following  the  assessment  of  the  2nd  and  3rd  PSUR,  to  include  under  section  4.8  rare 
adverse events of allergic type and transient nervous and visual disorders. The CPMP adopted a 
positive opinion for this variation on 27 July 2000. A revised Commission Decision was issued 
on 29 November 2000. 
1/2 
EMEA 2004 
 
• 
• 
• 
On 25 April 2000 the Marketing Authorisation Holder submitted to the EMEA an application 
for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995, as amended. The scope of this variation was a minor change in the manufacturing process 
of the active substance. This variation was approved by the EMEA on 26 May 2000 and did not 
require any amendments to the Commission Decision. 
On 28 April 2000 the Marketing Authorisation Holder submitted to the EMEA an application 
for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995, as amended. The scope of this variation was a change in the specification of the medicinal 
product.  This  variation  was a  consequence to a  follow up measure regarding  limit for percent 
polymers  and  aggregates  accepted  at  the  CPMP  meeting  held  in  January  2000.  This  variation 
was  approved  by  the  EMEA  on  31  May  2000  and  did  not  require  any  amendments  to  the 
Commission Decision. 
On 17 July 2000 the Marketing Authorisation Holder submitted to the EMEA an application for 
a  Type  I  variation  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10  March 
1995, as amended. The scope of this variation was a change in the name of the manufacturing 
site  of  the  finished  product  Optison  Molecular  Byosistems  Inc  to  Mallinckrodt  Inc.  This 
variation was approved by the EMEA on 9 August 2000 and did not require any amendments to 
the Commission Decision. 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Change in the name of the medicinal product (either invented name 
of common name): the MAH applied to change the name of the INN 
from octafluoropropane to perflutren, following a recommendation 
from the WHO INN Committee. 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 10.3 Notification) 
Change in the contact details of the local representatives on the 
package leaflet in all official languages.  
Transfer of MAH 
Bulk finished product manufacturing change 
Transfer of the manufacturing site for outer packaging and batch 
release 
Renewal  
Addition of new plasma sources 
Update of Summary of Product Characteristics and Package Leaflet 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
I/0016 
I  
14.05.01 
Commission 
Decision 
Issued/amended 
on 
-- 
N/0017 
N/0018 
T/0019 
II/0020 
I/0021 
R/0022 
II/0023 
II/0024 
N 
N 
T 
II 
I 
R 
II 
II 
05.06.01 
08.10.01 
13.03.02 
18.04.02 
26.03.02 
19.09.02 
15.01.03 
20.02.03 
25.09.03 
23.06.04 
29.04.02 
20.11.02 
17.03.03 
15.05.03 
26.09.03 
12.08.04 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
2/2 
EMEA 2004 
 
 
 
 
 
 
 
 
                                                           
 
